Literature DB >> 15923595

It is not time to stop progesterone receptor testing in breast cancer.

R Colomer, M Beltran, J Dorcas, H Cortes-Funes, J Hornedo, V Valentin, C Vargas, C Mendiola, E Ciruelos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15923595     DOI： 10.1200/JCO.2005.05.203

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

Review 1.  Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Authors:  Tessa G Steenbruggen; Mette S van Ramshorst; Marleen Kok; Sabine C Linn; Carolien H Smorenburg; Gabe S Sonke
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

2.  Biologic characteristics of premalignant breast disease.

Authors:  Kimberly Cole; Maria Tabernero; Karen S Anderson
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  A network-based pharmacological study on the mechanism of action of muscone in breast cancer.

Authors:  Yurong Zhao; Shuaixian Tao; Qiang Wang; Yan Liu; Wenke Yang; Shoude Zhang; Zhanhai Su; Xueman Ma
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 4.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

5.  Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

6.  A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

7.  The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer.

Authors:  M G Davey; É J Ryan; P J Folan; N O'Halloran; M R Boland; M K Barry; K J Sweeney; C M Malone; R J McLaughlin; M J Kerin; A J Lowery
Journal:  BJS Open       Date:  2021-05-07

8.  Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Authors:  Soo Youn Bae; Sangmin Kim; Jun Ho Lee; Hyun-Chul Lee; Se Kyung Lee; Won Ho Kil; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam
Journal:  BMC Cancer       Date:  2015-03-18       Impact factor: 4.430

Review 9.  Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.

Authors:  Xiaofeng Dai; Liangjian Xiang; Ting Li; Zhonghu Bai
Journal:  J Cancer       Date:  2016-06-23       Impact factor: 4.207

10.  Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.

Authors:  Ying Fan; Xiaoyan Ding; Binghe Xu; Fei Ma; Peng Yuan; Jiayu Wang; Pin Zhang; Qing Li; Yang Luo
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.